SCHEMBL11940879

SCHEMBL11940879

CC(C)S(=O)(=O)NC(=O)c1ccc2c(c1)C(C)(C)CC(c1cccc(N3CCOCC3)c1)N2

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP2C19 P33261 1/20 0.38
▸ F11 P03951 4/20 0.37
▸ F7 P08709 4/20 0.37
▸ F10 P00742 3/20 0.37
▸ HDAC3 O15379 1/20 0.36
▸ HDAC1 Q13547 1/20 0.36
▸ HDAC2 Q92769 1/20 0.36
▸ HDAC6 Q9UBN7 1/20 0.36
▸ MAPT P10636 4/20 0.36
▸ CYP3A4 P08684 2/20 0.35
▸ KMO O15229 1/20 0.35
▸ MTOR P42345 1/20 0.35
▸ PLOD2 O00469 2/20 0.35
▸ PLOD3 O60568 2/20 0.35
▸ PLOD1 Q02809 2/20 0.35
▸ KCNQ3 O43525 1/20 0.35
▸ KCNQ2 O43526 1/20 0.35
▸ CYP1A2 P05177 1/20 0.35
▸ CYP19A1 P11511 1/20 0.35
▸ CYP2C9 P11712 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11940880 0.89 CYP2C19 (0.40) CYP2C19F11F7F10HDAC3
SCHEMBL45312 0.88 F10 (0.47) CYP2C19F11F7F10HDAC3
SCHEMBL11026483 0.87 F10 (0.45) CYP2C19F11F7F10HDAC3
SCHEMBL45003 0.85 F10 (0.39) CYP2C19F11F7F10HDAC3
SCHEMBL41549 0.84 KMO (0.52) CYP2C19F11F7F10MAPT
SCHEMBL11024235 0.84 CYP2C19 (0.39) CYP2C19HDAC3HDAC1HDAC2HDAC6
SCHEMBL45781 0.84 F10 (0.45) CYP2C19F11F7F10MAPT
SCHEMBL11025709 0.84 F7 (0.44) CYP2C19F11F7F10MAPT
SCHEMBL45313 0.84 PRKD1 (0.40) CYP2C19HDAC3HDAC1MAPTCYP3A4
SCHEMBL45394 0.84 PRKD1 (0.40) CYP2C19HDAC3HDAC1MAPTCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8809369-B2 Tetrahydroquinoline derivatives HOFFMANN-LA ROCHE INC. (US) 2014-08-19 — — US disclosed
US-8809369-B2 Tetrahydroquinoline derivatives HOFFMANN-LA ROCHE INC. (US) 2014-08-19 — — US disclosed
WO-2012101068-A1 NOVEL TETRAHYDROQUINOLINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2012-08-02 — — WO disclosed
US-20120190677-A1 NOVEL TETRAHYDROQUINOLINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2012-07-26 — — US disclosed
US-20120190677-A1 NOVEL TETRAHYDROQUINOLINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2012-07-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190677-A1 NOVEL TETRAHYDROQUINOLINE DERIVATIVES RAB1A, RABL3, RAB7A CYP2C19 1776/4885F11 2989/4885F7 2297/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback